ALA — Arovella Therapeutics Income Statement
0.000.00%
Last trade - 00:00
- AU$109.16m
- AU$104.39m
- AU$0.44m
2019 June 30th | 2020 June 30th | 2021 June 30th | 2022 June 30th | 2023 June 30th | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | ARS | ARS | ARS | ARS | ARS |
Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 1.25 | 0.576 | 0.264 | 0.3 | 0.436 |
Cost of Revenue | |||||
Gross Profit | 1.05 | 0.375 | 0.041 | 0.093 | 0.232 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Depreciation and Amortization | |||||
Unusual Expense / Income | |||||
Other Operating Expenses | |||||
Total Operating Expenses | 9.88 | 11.2 | 6.01 | 8.73 | 11.6 |
Operating Profit | -8.63 | -10.6 | -5.75 | -8.43 | -11.2 |
Gain / Loss on Sale of Assets | |||||
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | -8.72 | -10.6 | -5.05 | -8.62 | -10.2 |
Provision for Income Taxes | |||||
Net Income After Taxes | -7.8 | -9.94 | -5.05 | -8.62 | -10.2 |
Net Income Before Extraordinary Items | |||||
Extraordinary Items | |||||
Net Income | -7.8 | -9.94 | -5.05 | -8.62 | -10.2 |
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | -7.8 | -9.94 | -5.05 | -8.62 | -10.2 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | -0.032 | -0.036 | -0.012 | -0.014 | -0.012 |